- |||||||||| [VIRTUAL] Past and current vaccine and immunotherapy development in Alzheimer’s disease () - Aug 7, 2020 - Abstract #CTAD2020CTAD_3;
Vaccine candidates such as CAD106 and UB-311 use selective epitopes and were developed to avoid the undesirable inflammatory effects that were seen with AN1792...Positive ADAS-cog effect sizes were seen for AN1792, Solanezumab EXPEDITION 3, BAN2401 and Aducanumab ENGAGE...Active vaccination achieving a predictable and high antibody response in amyloid positive, early AD participants increases the likelihood of technical success. The longer duration of immune response with active immunization combined with safety advantages make the modality well suited to AD
- |||||||||| UB-311 / Vaxxinity
Trial completion date, Trial termination, IO biomarker: An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311 (clinicaltrials.gov) - Dec 10, 2019 P2a, N=34, Terminated, The longer duration of immune response with active immunization combined with safety advantages make the modality well suited to AD Trial completion date: Apr 2020 --> Oct 2019 | Active, not recruiting --> Terminated; United Neuroscience has decided to terminate V203-AD-EXT study based on a treatment assignment error
- |||||||||| UB-311 / Vaxxinity
Enrollment closed, Trial completion date, Trial primary completion date, IO biomarker: An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311 (clinicaltrials.gov) - Sep 12, 2019 P2a, N=34, Active, not recruiting, Trial completion date: Apr 2020 --> Oct 2019 | Active, not recruiting --> Terminated; United Neuroscience has decided to terminate V203-AD-EXT study based on a treatment assignment error Enrolling by invitation --> Active, not recruiting | Trial completion date: Mar 2021 --> Apr 2020 | Trial primary completion date: Mar 2021 --> Oct 2019
- |||||||||| UB-311 / Vaxxinity
Trial completion, Trial completion date, Trial primary completion date: Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients (clinicaltrials.gov) - Jan 23, 2019 P2a, N=43, Completed, Enrolling by invitation --> Active, not recruiting | Trial completion date: Mar 2021 --> Apr 2020 | Trial primary completion date: Mar 2021 --> Oct 2019 Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> Aug 2018 | Trial primary completion date: Dec 2018 --> Aug 2018
- |||||||||| UB-311 / Vaxxinity
Enrollment status, Trial completion date, Trial initiation date, Trial primary completion date, IO biomarker: An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311 (clinicaltrials.gov) - Jan 23, 2019 P2a, N=41, Enrolling by invitation, Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> Aug 2018 | Trial primary completion date: Dec 2018 --> Aug 2018 Recruiting --> Enrolling by invitation | Trial completion date: Dec 2020 --> Mar 2021 | Initiation date: May 2018 --> Aug 2018 | Trial primary completion date: Nov 2020 --> Mar 2021
|